Dysfunction of interneurons has been implicated in various brain diseases, such as epilepsy, schizophrenia and autism [11], for which more effective treatments are desperately needed. Human pluripotent stem cells (hPSCs), especially human induced pluripotent stem cells (hiPSCs), provide an unprecedented opportunity to study disease mechanisms and develop novel therapeutics for these brain diseases [12–17], as long as specific neuronal subtypes can be efficiently derived from hiPSCs. We and others have recently reported on the efficient generation of MGE-type interneurons from hPSCs [18–21] by employing developmentally relevant signaling pathway activation, and the derivation of CGE-type interneurons using various methods [21–23].
